Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx has released new preclinical results for NCX 434 at the Retina International World Congress in Stresa, Italy, which showed a reduction in the retinal damage due to ischemia and reperfusion in a preclinical model without inducing an increase of intraocular pressure (IOP), in contrast to a reference steroid.
Subscribe to our email newsletter
NCX 434 is a nitric oxide (NO)-donating new molecular entity (NME) and a potential preclinical candidate in diabetic macular edema (DME).
NicOx’s new preclinical study demonstrated that NCX 434 was effective in reducing several biochemical and functional aspects of retinal damage in a preclinical model of ischemia/reperfusion induced by the injection of ET-1.
Additionally, NCX 434 did not change IOP in this model, while triamcinolone acetonide, a reference steroid, resulted in an increase in IOP.
The previous preclinical results showed that NCX 434 enhanced oxygen saturation in various optic nerve head structures in contrast to a reference steroid were presented recently at the Ocular Diseases & Drug Discovery conference in Boston.